Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Stable growth hormone compounds resistant to proteolytic degradation
US9211342B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9211342-B2 |
| Application number | US-201113574128-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 24, 2011 |
| Priority date | Jan 22, 2010 |
| Publication date | Dec 15, 2015 |
| Grant date | Dec 15, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A growth hormone compound comprising one or more additional disulfide bond(s) between a loop segment and a helical segment, or within a loop segment, or between loop segments, or between helical segments and at least one additional point mutation compared to human growth hormone (hGH) as defined by SEQ ID NO: 1, wherein said additional point mutation is present in a position selected from group consisting of 40, 41, 42, 55, 57, 62, 101, 134, 136, 139,…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9211342B2 cover?
- The present invention relates to growth hormone (GH) compounds having additional disulphide bridges and at least one additional single point mutation making the compounds resistant to proteolytic degradation.
- Who is the assignee on this patent?
- Demuth Helle, Schioedt Christine Brunn, Noerskov-Lauritsen Leif, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).